Valuation: VolitionRx Limited

Market Cap 6.46M 5.59M 5.22M 4.79M 9M 615M 9.14M 61.21M 24.02M 308M 24.25M 23.72M 1.02B P/E 2026 *
-0.35x
P/E 2027 * -0.56x
Enterprise Value 6.46M 5.59M 5.22M 4.79M 9M 615M 9.14M 61.21M 24.02M 308M 24.25M 23.72M 1.02B EV / Sales 2026 *
2.61x
EV / Sales 2027 * 1.13x
Free-Float
90.03%
Yield 2026 *
-
Yield 2027 * -
1 day+1.21%
1 week+7.97%
Current month+7.97%
1 month-44.62%
3 months-67.96%
6 months-84.24%
Current year-84.83%
1 week 0.71
Extreme 0.70995
0.91
1 month 0.69
Extreme 0.6901
1.53
Current year 0.69
Extreme 0.6901
7.73
1 year 0.69
Extreme 0.6901
15.1
3 years 0.69
Extreme 0.6901
27.6
5 years 0.69
Extreme 0.6901
82.8
10 years 0.69
Extreme 0.6901
136.8
Manager TitleAgeSince
Chief Executive Officer 55 05/10/2011
Director of Finance/CFO 56 31/01/2021
Chief Tech/Sci/R&D Officer 49 31/03/2024
Director TitleAgeSince
Director/Board Member 55 05/10/2011
Director/Board Member 77 05/10/2011
Director/Board Member 64 08/10/2019
Date Insider Type Main position Quantity % Market Cap.
17/03/26 Tax

Company Secretary

3,948 0.0029%
17/03/26 Tax

Chief Technology Officer

5,310 0.0039%
01/03/26
Concord International, Inc.
OtherCompany 0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+1.21%+7.97%-93.93%-96.85% 6.46M
+5.64%+10.46%+98.80%+272.09% 3.98B
+2.32%+1.94%+70.59%+90.48% 3.8B
+2.09%+55.77%+140.15%-10.07% 2.87B
+4.20%+6.82%+286.83%+332.31% 2.42B
+4.99%+4.72%-25.28%-32.77% 2.27B
+2.20%0.00%+5.49% - 1.26B
-0.32%-5.18%+207.65%-43.47% 919M
+0.70%+7.43%-3.67%+25.65% 934M
+3.09%+3.92%-37.86%-5.07% 532M
Average +2.61%+9.49%+64.88%+59.14% 1.9B
Weighted average by Cap. +3.35%+12.81%+98.63%+118.81%

Financials

2026 *2027 *
Net sales 2.48M 2.14M 2M 1.84M 3.45M 236M 3.51M 23.48M 9.22M 118M 9.3M 9.1M 391M 5.73M 4.96M 4.63M 4.25M 7.99M 546M 8.12M 54.34M 21.33M 273M 21.53M 21.06M 904M
Net income -22.2M -19.21M -17.94M -16.45M -30.95M -2.11B -31.44M -210M -82.59M -1.06B -83.38M -81.55M -3.5B -19.62M -16.97M -15.85M -14.54M -27.34M -1.87B -27.78M -186M -72.98M -936M -73.67M -72.06M -3.09B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
-
Date Price Change Volume
07/08/26 US$0.7753 +1.21% 456,431
06/08/26 US$0.7660 -3.65% 558,909
05/08/26 US$0.7950 +1.22% 9,938,048
04/08/26 US$0.7854 -1.81% 266,358
03/08/26 US$0.7999 +11.39% 203,212
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.7753USD
Average target price
16.97USD
Spread / Average Target
+2,088.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock